Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Central AHI Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) plus best supportive care vs best supportive care alone or inactive control Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Central AHI Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Physical activity interventions vs usual care Participant or parent satisfaction · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Physical activity interventions vs usual care Cost‐effectiveness · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Physical activity interventions vs usual care Delirium incidence or delirium‐free days at hospital discharge · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Physical activity interventions vs usual care Length of mechanical ventilation · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Physical activity interventions vs usual care Length of hospital stay · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Behavioral interventions vs usual care Cost‐effectiveness · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Behavioral interventions vs usual care Delirium incidence or delirium‐free days at hospital discharge · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Behavioral interventions vs usual care Length of mechanical ventilation · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Behavioral interventions vs usual care Length of hospital stay · children between the ages of 1 month and 18 years who were admitted to a pediatric inpatient setting from another… Non‐pharmacological interventions for sleep promotion in hospitalized children (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs placebo Non‐serious adverse events Timing of outcome assessment: end of treatment · people with borderline personality disorder Pharmacological interventions for people with borderline personality disorder (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants seizure‐free at 12 months after randomization ‐ not reported · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants with TEAEs leading to discontinuation during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants seizure‐free at 24 months after randomization ‐ not reported · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants seizure‐free at 24 months after randomization · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse (unintended) outcomes  · people approaching the end of life (within 12 months), their family members and/or carers Interventions for interpersonal communication about end of life care between health practitioners and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs no IVIG Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs no etanercept Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Time to complete re‐epithelialisation – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs no cyclosporin Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Disease‐specific mortality · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs corticosteroids Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |